Get the Stockscreener App
1.226
0.41%
-0.004
Allogene Therapeutics Inc stock is traded at $1.226, with a volume of 888.02K.
It is down -0.41% in the last 24 hours and up +8.41% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.23
Open:
$1.32
24h Volume:
888.02K
Relative Volume:
0.23
Market Cap:
$271.80M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.5783
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-11.23%
1M Performance:
+8.41%
6M Performance:
-15.52%
1Y Performance:
-53.77%
1-Day Range:
$1.20
$1.33
1-Week Range:
$1.20
$1.53
52-Week Range:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.225 | 272.91M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Chart based analysis of Allogene Therapeutics Inc. trendsJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - newser.com
What’s the recovery path for long term holders of Allogene Therapeutics Inc.July 2025 Review & Reliable Momentum Entry Alerts - newser.com
Published on: 2025-10-10 09:33:16 - newser.com
Applying sector rotation models to Allogene Therapeutics Inc.July 2025 Decliners & Weekly High Potential Stock Alerts - newser.com
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Is Allogene Therapeutics Inc. stock poised for growth2025 Price Targets & Technical Pattern Based Buy Signals - newser.com
Allogene, Pliant down as J.P. Morgan cuts to Underweight on uncertain outlook - Seeking Alpha
JP Morgan Downgrades Allogene Therapeutics (ALLO) to Underweight - GuruFocus
JPMorgan Downgrades Allogene Therapeutics to Underweight From Neutral - MarketScreener
What technical models suggest about Allogene Therapeutics Inc.’s comebackWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
Allogene Therapeutics Inc. stock volume spike explainedMarket Growth Report & Real-Time Volume Analysis - newser.com
Allogene Therapeutics' (ALLO) Sell (E+) Rating Reaffirmed at Weiss Ratings - MarketBeat
What analysts say about Allogene Therapeutics Inc stockFundamental Stock Analysis & Free Triple Digit Wealth Increase - earlytimes.in
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - MSN
Measuring Allogene Therapeutics Inc.’s beta against major indicesCEO Change & Consistent Profit Trade Alerts - newser.com
What does recent volatility data suggest for Allogene Therapeutics Inc.Portfolio Risk Report & Weekly Chart Analysis and Guides - newser.com
What indicators show strength in Allogene Therapeutics Inc.Weekly Profit Report & Fast Moving Market Watchlists - newser.com
Market reaction to Allogene Therapeutics Inc.’s recent newsMarket Weekly Review & AI Driven Price Predictions - newser.com
Published on: 2025-10-05 03:06:55 - newser.com
Allogene Therapeutics (NASDAQ:ALLO) Rating Increased to Hold at Wall Street Zen - MarketBeat
Allogene Therapeutics at Citi’s SMID Call Series: Strategic Insights By Investing.com - Investing.com Canada
Published on: 2025-10-03 05:33:11 - newser.com
Applying big data sentiment scoring on Allogene Therapeutics Inc.Short Setup & Capital Efficient Trade Techniques - newser.com
Published on: 2025-10-02 20:30:24 - newser.com
Published on: 2025-10-01 08:38:29 - newser.com
Analyzing net buyer seller activity in Allogene Therapeutics Inc.July 2025 Review & Daily Technical Forecast Reports - newser.com
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2025-09-29 14:28:46 - newser.com
Published on: 2025-09-29 11:38:34 - newser.com
Published on: 2025-09-29 07:57:40 - newser.com
Will Allogene Therapeutics Inc. stock beat EPS estimatesJuly 2025 Selloffs & Smart Allocation Stock Reports - The British Mountaineering Council
344,880 Shares in Allogene Therapeutics, Inc. $ALLO Purchased by Kingstone Capital Partners Texas LLC - MarketBeat
Real time scanner hits for Allogene Therapeutics Inc. explained2025 Technical Overview & Weekly High Return Forecasts - newser.com
Profit Recap: Can Allogene Therapeutics Inc. be the next market leaderPortfolio Performance Summary & AI Forecasted Stock Moves - khodrobank.com
Will Allogene Therapeutics Inc stock hit new highs in YEAR2025 Fundamental Recap & Reliable Breakout Forecasts - khodrobank.com
Custom watchlist performance reports with Allogene Therapeutics Inc.Insider Selling & Weekly Return Optimization Plans - newser.com
Update Report: Will Allogene Therapeutics Inc benefit from geopolitical trends2025 Market Sentiment & AI Driven Price Predictions - khodrobank.com
Allogene Therapeutics (NASDAQ:ALLO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Using fundamentals and technicals on Allogene Therapeutics Inc.Portfolio Profit Report & Weekly Top Performers Watchlists - newser.com
Aug PostEarnings: Can Allogene Therapeutics Inc reach resistance levels soonJuly 2025 Action & Low Risk Profit Maximizing Plans - خودرو بانک
History Review: Will Allogene Therapeutics Inc benefit from geopolitical trendsDip Buying & Weekly Momentum Stock Picks - خودرو بانک
Aug Reactions: What are the risks of holding Allogene Therapeutics Inc2025 Volume Leaders & Weekly Momentum Stock Picks - خودرو بانک
Bearish Setup: Will Allogene Therapeutics Inc stock hit new highs in YEAR2025 Price Momentum & Daily Oversold Bounce Ideas - خودرو بانک
Gainers Report: Will Allogene Therapeutics Inc outperform the market in YEAR2025 Macro Impact & Verified Entry Point Detection - خودرو بانک
Allogene reports promising results for CAR T therapy in lymphoma - MSN
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):